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Background: In sickle cell disease, the quantiﬁcation of Hb A2 is important for the differential
diagnosis between sickle cell anemia (Hb SS) and Hb S/0-thalassemia.
Objective: To determine Hb A2 levels as quantiﬁed by high performance liquid chromatogra-
phy in patients with sickle cell anemia (Hb SS) and with the SC hemoglobinopathy, with or
without concomitant alpha thalassemia.
Methods: This is a retrospective study of 242 children aged between two  and six years with
diagnoses of Hb SS or Hb SC. The hemoglobin was evaluated using high performance liquid
chromatography and alpha thalassemia [3.7 kb deletion (−3.7)] was detected by polymerase
chain reaction. Patients were classiﬁed as homozygous (−3.7/−3.7), heterozygous (−3.7/),
or  homozygous wild-type. Analysis of variance was used to compare the mean Hb A2 values
between the alpha thalassemia groups.
Results: The mean (± standard deviation) Hb A2 concentrations in the Hb SS group (n = 135)
was 3.68 ± 0.65%. The mean values for individuals with Hb SS and heterozygous (n = 28) or
homozygous for alpha thalassemia (n = 3) were 3.98 ± 0.64% and 4.73 ± 0.25%, respectively.
The  mean Hb A2 of all the Hb SC patients (n = 107) was 4.01 ± 0.507 with 4.29 ± 0.41% and
4.91  ± 0.22% in individuals heterozygous (n = 23) and homozygous for alpha thalassemia
(n  = 7), respectively. All patients homozygous for alpha thalassemia had Hb A2 levels above
3.5%. However, Hb A2 values above 5.2% were seen in patients with Hb SS and Hb SC,
independently of alpha thalassemia.
Conclusion: Hb A2 levels are elevated in patients with Hb S or Hb C, and are directly inﬂuenced
by  the alpha thalassemia genotypes.©  2015 Associac¸ão Bra
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ickle cell disease is one of the most common genetic
athologies in the world. It is characterized by homozygous
emoglobin S (Hb S) or Hb S associated to other Hb variants.1
here is great clinical variation in the clinical manifestations
etween sickle cell disease patients; several factors are asso-
iated with the different presentations. Some determinants
re already well established, such as genetic, clinical and
aboratory factors, while others, such as psycho-social and
utritional factors, have been less well studied.2–5
Of the genetic factors, the importance of the phenotype
f the hemoglobinopathy is well characterized in that indi-
iduals doubly heterozygous for sickle cell anemia and those
ith Hb S/0-thalassemia have a more  severe clinical proﬁle.
n the other hand, carriers of Hb SC together with Hb S/+-
halassemia have better outcomes, which makes the correct
iagnosis of these syndromes an issue of great importance for
 better understanding and adequate clinical and therapeutic
anagement of patients.4–6
In the diagnosis of sickle cell disease, quantiﬁcation of Hb
2, as well as a complete blood count (CBC), family history
nd clinical data, help to establish the differential diagnosis
etween sickle cell anemia (Hb SS) and Hb S/0-thalassemia.7,8
The choice of the methodology to accurately measure Hb
2 has been the subject of many  discussions in the medical lit-
rature, and high performance liquid chromatography (HPLC)
as been regarded the method of choice for many  years. The
eference value of Hb A2 in healthy adults who do not have
halassemia is usually between 2.0 and 3.3%.5,9–12
In 1996, Suh et al.13 reported that Hb A2 values obtained
y HPLC increased signiﬁcantly in samples containing Hb S
nd suggested the possibility that Hb SS individuals may have
een incorrectly diagnosed with Hb S/0-thalassemia. They
lso suggested that increases in Hb A2 could be explained by
he presence of smaller components of Hb S that co-eluted
ith Hb A2.
In 2000, Shokrani et al.14 proposed that blood samples
ith Hb values of up to 5.9% and up to 5.2% of Hb A2 as
nalyzed by HPLC from Hb SS or Hb SC patients and indi-
iduals with the sickle cell trait (Hb AS), respectively can be
onsidered normal. In 2004, Head et al.7 conﬁrmed the ﬁnd-
ngs of Shokrani et al. and explained that the falsely elevated
b A2 values were due to the presence of Hb S that had
uffered post-translational modiﬁcations, and consequently
ad the same retention time as Hb A2. They also demon-
trated that the degree of uncertainty directly correlated to
he concentration of Hb S, which is higher in Hb SS patient
amples than in samples from individuals with Hb AS. Addi-
ionally, they concluded that the percentage of Hb A2 is higher
n Hb AS individuals with alpha thalassemia (AT) than in
hose without AT; and suggested that this occurs because the
elta chains have greater afﬁnity to alpha chains than the S
hains.7
More  recently, studies using mass spectrometry have pro-
osed that elevated Hb A2 values in samples with Hb S can be a
onsequence of the elution of smaller Hb components formed
y a S chain associated with an alpha-globin chain that was
odiﬁed by carbamylation after translation.15 1 5;3  7(5):296–301 297
The interference of anomalous Hb in the quantiﬁcation of
Hb A2 is not limited to the presence of Hb S and Hb C, but can
also be related to the presence of other beta chain variants
such as Hb E, Hb D and Hb Lepore.16,17
In 2007, Ondei et al.,18 in an effort to establish reference
values for the Brazilian population, used HPLC to analyze 136
samples with the Hb AS phenotype, 106 with AT and Hb AS,
18 with Hb SS and nine with Hb SC, and concluded that Hb
A2 values of 2.9–5.2% for Hb AS, 2.8–5.2% for AT together with
Hb AS, 0.8–5.6% for Hb SS and 3.8–5.7% for Hb SC should be
considered normal.
Considering the widespread use of HPLC in the labora-
tory practice and the importance of an accurate diagnosis to
deﬁne the type of sickle cell disease in order to facilitate better
clinical and laboratory follow-up of these patients, the cur-
rent study sought to verify the Hb A2 values as quantiﬁed by
HPLC, in samples of patients with Hb S and Hb  C, in the pres-
ence or absence of the 2-thalassemia 3.7 kb deletion as both
hemoglobinopathies may be prevalent in the same popula-
tion.
Methods
Study  design  and  population
This is a retrospective study conducted between June 2008
and June 2009 with an initial sample composed of 287 chil-
dren. Forty-ﬁve were excluded: eight for presenting a diagnosis
of Hb S/-thalassemia, eleven for having been analyzed by
HPLC after the transfusion of blood components, and 26
due to iron deﬁciency. This left a total of 242 children diag-
nosed with sickle cell anemia or Hb SC screened and followed
at the Neonatal Screening Referral Service (SRTN) of the
Associac¸ão de Pais e Amigos dos Excepcionais in Salvador
(APAE/Salvador), Bahia, Brazil. The SRTN-APAE/Salvador is
registered with the Brazilian Ministry of Health (Ordinance 822
– 06/06/2001) as a referral service in the state of Bahia, Brazil.
This service diagnoses and follows up all newborns with sickle
cell anemia in Bahia, the state with the highest incidence of
this hemoglobinopathy in Brazil (one in 601 newborns/year).19
The objectives and procedures involved in the study were
explained, and parents who agreed to participate signed an
informed consent form. All parents of participating children
were asymptomatic, and were subjected to a CBC, Hb proﬁling,
and measurement of serum ferritin. All presented a laboratory
proﬁle compatible with heterozygosity for Hb S or Hb C and
normal iron reserves.
Analyses  and  laboratory  techniques
Venous blood samples were collected in 3.0-mL tubes contain-
ing 3.6 mg  K2-ethylenediaminetetraacetic acid (EDTA) as an
anticoagulation agent and in a tube with a gel separator. The
qualitative and quantitative Hb proﬁles were investigated by
automated HPLC using the Variant Express apparatus and the
-thalassemia Short Program kit (Bio-Rad, California, USA).
Cation-exchange HPLC is a process in which a mixture of
molecules (such as normal and variant Hbs) with a net pos-
itive charge is separated into its components by adsorption
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Table 1 – Distribution of 3.7-thalassemia in 242 children with sickle cell disease.
Sickle cell disease 3.7-Thalassemia p-Value
/ −/ −/−
n % n % n %
Hb SS 104 77.0 28 20.7 3 2.2
0.233
Hb SC 77 72.0 23 21.5 7 6.5
Total 181 74.8 51 21.0 10 4.1Hb SS: sickle cell anemia; Hb SC: SC hemoglobinopathy.
of molecules in a negatively charged stationary phase in a
chromatography column, followed by their elution in a mobile
phase. In the mobile phase a liquid with an increased con-
centration of cations ﬂows through the column; the cations
in the mobile phase compete with the adsorbed proteins for
anionic binding sites. Thus, the adsorbed positively charged
Hb molecules are eluted from the column into the liquid
phase at a rate related to their afﬁnity in the stationary phase.
The different Hbs eluted from the column are represented
graphically and automatically quantiﬁed. The result is a chro-
matogram with the percentage and retention time of each Hb
fraction. The time of elution (retention time) of any normal or
variant Hb present is compared with that of known Hbs pro-
viding quantiﬁcation of normal Hbs (Hb A, Hb F, and Hb A2)
and many  variants. The most positively charged Hbs (e.g. Hb S
and Hb C) have a longer retention time.20
Patient samples were considered to contain Hb S and/or
Hb C when the chromatograms presented variants with reten-
tion times equivalent to these Hbs. As such, the diagnosis of
sickle cell anemia was made only if Hb S, Hb F and Hb A2 were
present, hemametric indices of the CBC were normal, and
the parents presented normal CBCs with Hb proﬁle consistent
with sickle cell trait. The serum ferritin level was determined
by chemoluminescence (ADVIA Centaur CP System, Siemens).
Ferritin levels <12 ng/mL were considered as iron deﬁcient.21
The deletion of 3.7 kb in AT was investigated by
allele-speciﬁc polymerase chain reaction (PCR)22 and the
participants were identiﬁed as heterozygotes (−3.7/),
homozygotes (−3.7/−3.7) or wild type (/).
Statistical  analysis
Hb A2 concentrations were described according to the type of
sickle cell disease (Hb SC or Hb SS) together with AT status
(wild-type, heterozygous or homozygous) using central ten-
dency analysis and dispersion. The Kolmogorov–Smirnov test
was used for analysis of normal distribution. One-way analysis
of variance (ANOVA) was used to analyze differences between
groups, and two-way ANOVA was used to analyze the inﬂu-
ence of the interaction and confounding factors between type
of sickle cell anemia and presence of AT (independent vari-
ables) on Hb A2 levels (dependent variable). Post hoc analysis
was performed using Tukey’s Honestly Signiﬁcant Difference
(HSD) test and the Games–Howell test to identify situations in
which equality of variance was veriﬁed. Due to the reduced
size of the group with homozygous mutations, statistical sig-
niﬁcance was set at a p-value <0.01.Hb A2 values were categorized in three groups based on
standard reference values: (1) below 2.0%; (2) between 2.0
and 3.5%; and (3) above 3.5%. These categories were analyzed
according to the AT data using the chi-squared tendency test.
All data were analyzed using EPI INFO for Windows (version
3.5.1) and the Statistical Package for the Social Sciences (SPSS®
– version 13.0).
Ethical  considerations
The present study was approved by the Ethics Commit-
tee for Research in Human Beings of the Gonc¸alo Moniz
Research Center from the Oswaldo Cruz Foundation, Bahia
(CEP-CPqGM/FIOCRUZ: protocol #112/2006) and followed the
research ethics guidelines as deﬁned in resolution 196/96 of
the Helsinki declaration of 2008.
Results
The ﬁnal cohort analyzed consisted of 242 patients (107 Hb SC
and 135 Hb SS) aged from two to six years with an average age
of 3.05 years (±1.01), and median (p25–p75) of 4 (3.0–5.0) years.
The distribution of 3.7-thalassemia is described in Table 1.
There was no signiﬁcant difference between the distribu-
tion of heterozygous or homozygous AT between the two
types of hemoglobinopathies (Hb SS and Hb SC) (2 = 2.917;
p-value = 0.233).
The mean Hb A2 level in Hb SS samples independently of
the presence of AT (n = 135) was 3.68% (±0.65); in Hb SS samples
with heterozygous AT (n = 28) it was 3.98% (±0.64) and in Hb SS
samples with homozygous AT (n = 3) it was 4.73% (±0.25). The
mean Hb A2 in all Hb SC samples (n = 107) was 4.01% (±0.50);
in Hb SC samples with heterozygous AT (n = 23) it was 4.29%
(±0.41), and in Hb SC samples with homozygous AT (n = 7) it
was 4.91% (±0.22).
With regard to the mean Hb A2 values and the sickle cell
disease type (Hb SS or Hb SC), signiﬁcantly higher overall val-
ues were observed in patients with Hb SC compared to Hb
SS (p-value <0.001) as shown in Table 2. When the data were
stratiﬁed according to the AT status (wild type, heterozygous
or homozygous), a signiﬁcant difference was observed only
when samples without AT were compared. Values were not
signiﬁcant for heterozygous (Hb SC: 4.29 ± 0.41% versus Hb SS:
3.98 ± 0.64%; p-value = 0.074), or for homozygous AT mutation
(Hb SC: 4.91 ± 0.22% versus Hb SS: 4.73 ± 0.25%; p-value = 0.267
– Table 2).
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Table 2 – Mean, standard deviation, maximum and minimum values for Hb A2 in 242 children according to the presence
of 3.7-thalassemia, stratiﬁed by type of sickle cell disease.
3.7-Thalassemia n Average SD Minimum–maximum p-Value
<0.001a
/ 181 3.68 0.56 1.50–5.20
0.001bHb SS 104 3.57 0.61 1.50–5.20
Hb SC 77 3.84 0.42 2.90–4.80
−/ 51 4.12 0.57 2.30–4.90
0.074bHb SS 28 3.98 0.64 2.30–4.90
Hb SC 23 4.29 0.41 3.30–4.90
−/− 10 4.86 0.23 4.50–5.20
0.267bHb SS 3  4.73 0.25 4.50–5.00
Hb SC 7 4.91 0.22 4.60–5.20
Total 242 3.82 0.62 1.50–5.20
<0.001cHb SS 135 3.68 0.65 1.50–5.20
Hb SC 107 4.01 0.51 2.90–5.20
SD: standard deviation; Hb SS: sickle cell anemia; Hb SC: SC hemoglobinopathy.
a Comparison of average Hb A2 values according to presence of 3.7-thalassemia (wild-type, heterozygous and homozygous) independently of
type of hemoglobinopathy – non-parametric Kruskal–Wallis test.
b Comparison of average Hb A2 values between the types of hemoglobinopathy (Hb SS or Hb SC) for each alpha thalassemia classiﬁcation
(wild-type, heterozygous and homozygous) – non-parametric Mann–Whitney test.
c Comparison of average Hb A2 values between the types of hemoglobino
cation (wild-type, heterozygous and homozygous) – non-parametric Ma
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Figure 1 – Hb A2 values (%) according to 3.7-thalassemia
genotype and sickle cell type (Hb SS/Hb SC) in 242 children.
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background and clinical history (including family history) and
the results of the physical examination combined with rela-When comparing groups according to AT status only (wild-
ype, heterozygous or homozygous), higher mean values were
bserved for Hb A2 in patients with the −/− genotype
F = 30.985; p-value <0.001 – Table 2).
The analysis of the interaction between the type of sickle
ell disease and AT genotype was carried out after the differ-
nce between the average Hb A2 values for Hb SS and Hb SC
as found to be signiﬁcant. There was no signiﬁcant inter-
ction (F = 0.583; p-value = 0.559) or inﬂuence of the type of
emoglobinopathy (F = 2.156; p-value = 0.43) on the mean Hb
2 values. Only the AT genotype inﬂuenced the variation of
he mean Hb A2 values (F = 28.676; p-value <0.001). The post hoc
nalysis indicated a signiﬁcant difference between the three
T genotype groups, showing a progressive increase in Hb A2
evels (Figure 1).pathy (Hb SS or Hb SC) independently of alpha thalassemia classiﬁ-
nn–Whitney test.
Using the reference Hb A2 values described by Ondei et al. in
2007,18 it was observed that all homozygous mutant samples
had elevated Hb A2 levels (above 3.5%), and a tendency for
increases in the percentage of children with Hb A2 levels above
3.5% from the wild-type (59.7%) to the heterozygous (88.2%)
and the homozygous (100%) samples (2linear tendency = 18.871;
p-valuetendency < 0.001), as shown in Table 3.
Discussion
Hb disorders are recognized as one of the most common inher-
ited diseases worldwide. Among the hemoglobinopathies,
sickle cell disease and -thalassemia have the greatest impact
on morbidity and mortality, affecting millions of individuals
worldwide.5
Sickle cell disease should be considered as both a qualita-
tive and quantitative genetic disorder in that it is caused by
the presence of an abnormal Hb variant – Hb S. Homozygosity
for Hb S or sickle cell anemia is the most common genotype;
the other causative genotypes include compound heterozy-
gous states of Hb S with Hb C (Hb SC) or -thalassemia variants
(Hb S/0-thalassemia and Hb S/+-thalassemia).5
Diagnosis of speciﬁc sickle cell diseases is accomplished by
integrating clinical and hematological parameters along with
laboratory Hb analysis. Combining these elements to prop-
erly diagnose Hb disorders is essential for the treatment of
anemia, primary prevention and genetic counseling for under-
lying disorders. In the majority of patients, the presence of a
hemoglobinopathy can be diagnosed with sufﬁcient accuracy
for clinical purposes from knowledge of the patient’s ethnicaltively simple blood tests. Initial investigations should include
determination of Hb concentration and red cell indices. A
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Table 3 – Proportion of Hb A2 above 3.5% found in 242 according to the presence of 3.7-thalassemia.
Hb A2
3.7-Thalassemia <2.0%
n (%)
2.0–3.5%
n  (%)
>3.5%
n  (%)
p-Value
/ (n = 181) 1 (0.6) 72 (39.8) 108 (59.7)
<0.001a−/ (n = 51) – 6 (11.8) 45 (88.2)
−/− (n = 10) – – 10 (100.0)
Total 1 (0.4) 78 (32.2) 163 (67.4)
Fundinga Chi-squared linear tendency test.
detailed examination of a well-stained blood ﬁlm should be
carried out. Other important basic tests are Hb electrophore-
sis or chromatography, and the measurement of Hb A2 and
Hb F.23 Automated HPLC, by analyzing large numbers of sam-
ples, is increasingly replacing Hb electrophoresis as the initial
investigative procedure in laboratories.18,23
While HPLC is considered a method that permits rapid and
precise detection of Hb variants, as well as sensitive quantiﬁ-
cation of Hb A2,9 over the last two decades various authors
have reported the occurrence of falsely elevated Hb A2 in
screening for Hb variants (Hb S, Hb C, Hb D, Hb E and Hb Lep-
ore) and for AT. Some of these authors have cautioned about
the risk of interpretation errors and the false diagnosis of Hb
S/0- thalassemia.7,10,13,14,16–18,24–26
Accurate diagnosis of Hb disorders is essential in sickle
cell syndromes. Considering the clinical importance of Hb A1
and Hb A2 and/or Hb F together with clinical and laboratory
data for the diagnosis of Hb S/-thalassemia, this study ana-
lyzed Hb A2 values by HPLC in conjunction with Hb S and Hb
C, and AT, in a population with a low estimated frequency
of -thalassemia.27,28 Similar to results observed in previous
studies,7,10,13,14,16–18,24–26 the Hb A2 values obtained by HPLC
were increased in Hb SS and Hb SC patient samples.
2-Thalassemia was diagnosed in 23.4% of the children
with sickle cell disease, a result that agrees with previous
studies performed in the population of the state of Bahia,
Brazil.29,30 Thus, as Suh et al.13 and Ondei et al.18 stated, the
presence of AT has an impact on the value of Hb A2 as quanti-
ﬁed by HPLC and additionally, in the present study, signiﬁcant
differences in the mean levels of Hb A2 were observed accord-
ing to the presence of 3.7-thalassemia, with a gradual increase
in this Hb fraction between the three groups: wild type to het-
erozygous to homozygous.
Several studies in recent years9–12 have sought to compare
different methodologies and systems in order to identify pro-
cesses in which the presence of anomalous Hbs have the least
effect on the measurement of Hb A2 in order to reach a more
accurate diagnosis. However, studies seeking to explain how
the presence of these Hbs and AT may result in false Hb A2
levels are extremely scarce. Even the most recent publications,
such as that of Greene et al. in 20155 seem to agree with Suh
et al. from 199613 in attributing the apparent increase in Hb
A2 as quantiﬁed by HPLC in samples containing Hb structural
variants to the presence of glycosylated fractions of anoma-
lous Hb (such as Hb S1c) that co-elute with Hb A2.10,14,17,23On comparing the impact of the type of Hb variant on the
measurement of Hb A2, the greatest impact was caused by the
presence of AT, and not by Hb S or Hb C. Head et al. 7 defended
that the increased Hb A2 levels observed in the association
of sickle cell disease with AT are explainable in that with a
lower number of alpha chains being produced, these positively
charged molecules combine with other chains for which they
have great afﬁnity, namely the delta chains.
The prevalence of -thalassemia is very low in the studied
population,27,28 and a careful hematological study of the par-
ents showed normal erythrograms and the presence of Hb S
and Hb A consistent with heterozygosity for Hb S. Given these
facts, we consider that the Hb A2 values seen in the patients
were falsely elevated due to interference of the methodology
used in the presence of structural Hb variants and AT, and as
such the patients can be diagnosed as having sickle cell ane-
mia, and not Hb S/0-thalassemia, even though we  recognize a
limitation by the fact that we did not perform molecular anal-
yses to conclusively exclude the diagnosis of -thalassemia.
We suggest that in cases with a possible diagnosis of Hb  S/0
thalassemia, the Hb proﬁle should not be performed by HPLC,
or that if used, this method should be complemented by a sec-
ond conﬁrmatory test. Furthermore, when doubts still remain,
a molecular analysis should be carried out to identify deletions
or other mutations, in order to conﬁrm the clinical diagnosis
and guide genetic counseling.5
Conclusion
We conclude that the Hb A2 levels in samples containing Hb
S and/or Hb C can be overestimated when analyzed by HPLC,
especially in the presence of AT, and that in these situations
the reference values of up to 3.5% should not be used. We
reinforce the importance of multi-center studies when estab-
lishing patterns, the need for individual evaluations of cases
in order to reach a differential diagnosis between sickle cell
syndromes, especially in regions with a high prevalence of the
different types of hemoglobinopathies, and the use of molec-
ular biology studies to clarify any doubts.Centro Nacional de Desenvolvimento Cientíﬁco e Tecnológico
(CNPq).
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